Application of G-CSF in high-leukocyte acute myeloid leukemia is a poor prognostic factor

Figures & data

Table 1. Baseline characteristics of patients.

Baseline characteristics	G-CSF group (N=355)	No G-CSF group (N=171)	Total (N=526)	p
Age				0.101
<40	166	93	259 (49.2%)
≥40	189	78	267 (50.8%)
Sex				0.797
Male	193	95	238 (54.8%)
Female	162	76	288 (45.2%)
FAB				0.611
M0	4	5	9 (1.7%)
M1	25	9	34 (6.5%)
M2	102	49	151 (28.7%)
M4	9	6	15 (2.9%)
M5	196	96	292 (55.5%)
M6	10	4	14 (2.7%)
M7	1	1	2 (0.4%)
Undefined	8	1	9 (1.7%)
Initial leukocytes				0.500
<50×10^9/L	270	115	385 (73.19%)
>50×10^9/L	85	56	141 (26.81%)
Hemoglobin (g/L)	77.65	77.62		0.994
Platelet(×10^9/L)	63.47	68.77		0.406
Hyperplasia				0.328
Extremely active	186	99
Obviously active	87	34
Active	62	30
Reduced	18	6
Extremely reduced	2	2
Bone marrow blasts	66.73	67.50		0.697

Table 2. Cox regression analysis of CR1 stage in AML patients.

Factor classification	p	OR
Initial leukocyte number	0.018*	1.716
G/GM-CSF	0.040*	1.546

Figure 1. Effect of G-CSF on CR1 stage in AML patients with high leukocytes.

Table 3. Cox regression analysis of survival stage in AML patients.

Factor classification	p	OR
Initial leukocyte number	0.047*	1.468
G/GM-CSF	0.039*	1.448

Figure 2. Effect of G-CSF on OS in AML patients with high leukocytes.

Data availability statement

The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.